Comparative Pharmacology
Head-to-head clinical analysis: CARDRASE versus TAMBOCOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARDRASE versus TAMBOCOR.
CARDRASE vs TAMBOCOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CARDRASE is a nonsteroidal anti-inflammatory drug that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), thereby reducing the synthesis of prostaglandins involved in inflammation, pain, and fever.
Class Ic antiarrhythmic agent; blocks sodium channels, slowing conduction velocity and prolonging refractoriness in cardiac tissues.
Adult: 100 mg orally twice daily.
For atrial fibrillation/flutter: 50 mg orally every 12 hours; may increase by 50 mg every 4 days up to 300 mg/day. For life-threatening ventricular arrhythmias: 100 mg orally every 12 hours; increase by 50 mg every 4 days up to 400 mg/day.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours in adults with normal renal function; prolonged to 24-40 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life: 12–27 hours (mean 20 hours); prolonged to 58 hours in heart failure or renal impairment (CrCl < 35 mL/min).
Primarily renal excretion of unchanged drug (60-70%) and glucuronide conjugate (10-20%); biliary/fecal elimination accounts for 10-15%.
Renal: 85% (30% unchanged, 55% as inactive metabolites); Fecal: 5%; Biliary: negligible.
Category C
Category C
Antiarrhythmic Agent
Antiarrhythmic Agent